Physician profile
Amy Devore
NPI 1063559441
$39,766.49
in general payments reported to CMS, 2019-2025
26 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $1,602 · 2021: $1,355 · 2022: $1,342 · 2023: $1,248 · 2024: $1,419 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.48 |
| Education | $360.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32,368.05 | 2019-2024 | |
| Abbvie INC. | $1,780.28 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,552.55 | 2019-2025 | Tremfya |
| Genzyme Corporation | $485.77 | 2020-2025 | |
| Amgen INC. | $480.61 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $375.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $312.46 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $261.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $249.55 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $225.00 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $222.65 | 2020-2024 | |
| Galderma Laboratories, L.P. | $205.84 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $200.72 | 2023-2025 | Zoryve |
| Biofrontera INC. | $162.21 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.44 | 2022-2025 | Spevigo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $142.27 | 2020-2023 | Adbry |
| Celgene Corporation | $136.22 | 2019 | |
| Almirall LLC | $103.14 | 2019-2024 | Klisyri |
| Dermavant Sciences, INC. | $87.11 | 2023-2024 | Vtama |
| Incyte Corporation | $77.95 | 2022-2023 | Opzelura |
| Organogenesis INC. | $51.02 | 2021-2025 | Affinity |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.48 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $25.57 | 2020 | |
| Kci USA, INC. | $25.46 | 2023 | Promogran Prisma, Activ.A.C. |
| Organon LLC | $24.13 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $20.44 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.